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Abstract
 
The promyelocytic leukemia
 
 
 
retinoic acid receptor 
 
a
 
 (PMLRAR
 
a
 
) chimeric protein is associ-
 
ated with acute promyelocytic leukemia (APL). 
 
PMLRAR
 
a
 
 
 
transgenic mice develop leukemia
only after several months, suggesting that PMLRAR
 
a
 
 does not by itself confer a fully malig-
nant phenotype. Suppression of apoptosis can have a central role in tumorigenesis; therefore,
we assessed whether BCL-2 influenced the ability of PMLRAR
 
a
 
 to initiate leukemia. Evalua-
tion of preleukemic animals showed that whereas PMLRAR
 
a
 
 alone modestly altered neutro-
phil maturation, the combination of PMLRAR
 
a
 
 and BCL-2 caused a marked accumulation of
immature myeloid cells in bone marrow. Leukemias developed more rapidly in mice coex-
pressing PMLRAR
 
a
 
 and BCL-2 than in mice expressing PMLRAR
 
a
 
 alone, and all mice ex-
pressing both transgenes succumbed to leukemia by 7 mo. Although both preleukemic, doubly
transgenic mice and leukemic animals had abundant promyelocytes in the bone marrow, only
leukemic mice exhibited thrombocytopenia and dissemination of immature cells. Recurrent
gain of chromosomes 7, 8, 10, and 15 and recurrent loss of chromosome 2 were identified in
the leukemias. These chromosomal changes may be responsible for the suppression of normal
hematopoiesis and dissemination characteristic of the acute leukemias. Our results indicate that
genetic changes that inhibit apoptosis can cooperate with PMLRAR
 
a
 
 to initiate APL.
Key words: leukemia • myeloid/leukemia • promyelocytic • acute/leukopoiesis/PML 
protein/receptors • retinoic acid
 
Introduction
 
Many genetic alterations have been associated with acute
 
myeloid leukemia (AML)
 
1
 
 (1, 2). Nevertheless, our under-
standing of the combinations of changes sufficient to fully
transform myeloid cells remains limited. The t(15;17)(q22;
q11.2) chromosomal translocation is closely associated with
human acute promyelocytic leukemia (APL; reference 3).
This translocation fuses the gene encoding promyelocytic
leukemia 
 
(
 
PML), a protein that limits proliferation and in-
duces apoptosis, with the gene encoding the retinoic acid
receptor 
 
a
 
 (RAR
 
a
 
), a hormone receptor that represses
transcription in the absence of retinoic acid and activates
transcription in response to this ligand. A PMLRAR
 
a
 
 fu-
sion protein is expressed in almost all cases of APL, and this
protein can initiate acute leukemias with promyelocytic
features when expressed in mice (4–6).
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Abbreviations used in this paper:
 
 7-AAD, 7-amino actinomycin D;
AML, acute myeloid leukemia; APL, acute promyelocytic leukemia;
 
PML, promyelocytic leukemia; RAR
 
a
 
, retinoic acid receptor 
 
a
 
; tRA,
all-trans retinoic acid.
 532
 
BCL-2 Cooperates with PMLRAR
 
a
 
PMLRAR
 
a
 
 is thought to contribute to leukemogenesis
primarily by inhibiting neutrophilic differentiation. Reti-
noids can induce differentiation of myeloid and other cell
types (7). PMLRAR
 
a
 
 inhibits differentiation of myeloid
cell lines (8–11), and all-trans retinoic acid (tRA) binding
to PMLRAR
 
a
 
 results in transcriptional activation and neu-
trophilic differentiation (3, 12–14). Nevertheless, mice ex-
pressing PMLRAR
 
a
 
 exhibited only mild abnormalities be-
fore the appearance of acute leukemia (which arises with
limited penetrance only after several months; references
4–6), suggesting that additional genetic changes cooperate
with PMLRAR
 
a
 
 to block differentiation.
PMLRAR
 
a
 
 may also contribute to leukemogenesis by
enhancing the survival of immature myeloid cells. Whereas
PMLRAR
 
a
 
 induces apoptosis of nonhematopoietic and
some hematopoietic cell lines (15), PMLRAR
 
a
 
 confers in-
creased resistance to apoptosis in myeloid cell lines in
which its expression is tolerated (8, 16). PMLRAR
 
a
 
 also
enhances survival of primary myeloid CFU in response to
proapoptotic stimuli (17) and hematopoietic progenitor
cells after growth factor deprivation (18). PMLRAR
 
a
 
-
mediated suppression of apoptosis might influence the abil-
ity of this fusion protein to initiate leukemia.
BCL-2 protects cells from apoptosis by inhibiting the ac-
tivation of caspases necessary to execute a cell death pro-
gram (19). In follicular lymphoma, BCL-2 is overexpressed
as a result of a t(11;14)(q32;q21) chromosomal transloca-
tion. BCL-2 expression has also been observed in AMLs,
including leukemic cells of some APL patients, and such
expression has been associated with poor prognosis (20–
26). Thus, BCL-2, or related proteins, may play a role in
the pathogenesis of a subset of APL and might influence
the response of patients to therapy.
Transgenic mice expressing 
 
PMLRAR
 
a
 
 under the con-
trol of the 
 
MRP8
 
 promoter were bred with 
 
MRP8-BCL-2
 
transgenic mice to assess whether BCL-2 could cooperate
with PMLRAR
 
a
 
 to initiate leukemia. We observed that
coexpression of BCL-2 and PMLRAR
 
a
 
 caused a marked
accumulation of immature myeloid cells. Furthermore,
BCL-2 accelerated the development of acute leukemia in
mice that express PMLRAR
 
a
 
.
 
Materials and Methods
 
Mice. 
 
Mice were bred and maintained at the University of
California at San Francisco and their care was in accordance with
University of California at San Francisco guidelines. 
 
MRP8-PML-
RAR
 
a
 
 transgenic mice (4) were bred with 
 
MRP8-BCL-2 
 
trans-
genic mice (27) to generate the litters of control, singly trans-
genic, and doubly transgenic mice used for experiments.
 
Preparation of Tissues for Analysis.
 
Blood was obtained from
anesthetized animals by venipuncture of the retroorbital venous
plexus. Bone marrow was obtained by flushing HBSS through
mouse long bones. Blood smears and bone marrow smears were
prepared according to standard hematological techniques. Ster-
nums were decalcified for 2–3 h (formic acid 11%, formaldehyde
8%). Sternums, livers, spleens, and kidneys were fixed overnight
in buffered formalin and embedded in paraffin before sectioning.
 
Peripheral Blood Counts and Bone Marrow Differential Counts
 
.
 
Blood counts of nonleukemic, preleukemic, and some leukemic
mice were obtained on automated hematology analyzers running
veterinary software (Cell-Dyne3500, Abbott; Hemavet 850,
CDC Technologies). Blood counts of leukemias that arose early
in the study were obtained on a Technicon H-3 automated he-
matology analyzer running the standard software used for clinical
analysis. Peripheral blood differential white blood cell counts (to-
tal of 200 cells each) and bone marrow differential counts (total of
400 cells each) were performed on stained smears as described
(28).
 
Analysis of Proliferation.
 
Bone marrow cells were fixed in ice-
cold 70% ethanol for 30 min. After two washes in PBS, cells were
resuspended in PBS containing 50 
 
m
 
g/ml propidium iodide
(Boehringer) and 10 
 
m
 
g/ml RNase (Sigma-Aldrich). After a 30-
min incubation, cells were analyzed using a FACScan™ flow cy-
tometer (Becton Dickinson) and cell cycle distribution of 10,000
events was assessed using Modfit software (Becton Dickinson).
 
Analysis of Apoptosis.
 
Immediately after harvest, bone marrow
cells were washed twice in PBS with 2% heat-inactivated fetal
bovine serum (wash buffer), and cells were then stained with
FITC-conjugated antibodies to CD18 or an isotype control (BD
PharMingen) for 20 min on ice. Then, cells were washed and
stained for 30 min in the dark, on ice, with 20 
 
m
 
g/ml 7-amino
actinomycin D (7-AAD; Calbiochem). After being washed twice,
cells were resuspended in wash buffer containing 10 
 
m
 
g/ml acti-
nomycin D (Calbiochem). Analysis was carried out using a FAC-
Scan™ flow cytometer within 1 h of staining. 50,000 events were
analyzed using CELLQuest™ software (Becton Dickinson).
CD18
 
1
 
 cells were gated and three populations were identified:
7-AAD
 
low
 
 live nonapoptotic cells; 7-AAD
 
moderate
 
 apoptotic cells;
and 7-AAD
 
bright
 
 dead cells (29).
 
Methylcellulose Cultures of Bone Marrow.
 
As described previ-
ously (28), bone marrow cells were cultured in duplicate in 35-
mm petri dishes in Methocult M3230 methylcellulose medium
(StemCell Technologies Inc.) supplemented with either 50 U/ml
of G-CSF (Boehringer) or 20 ng/ml GM-CSF (StemCell Tech-
nologies Inc.). 1-ml cultures contained 50,000 viable bone mar-
row cells. Cultures were examined at 7 d. Colonies were counted
on an inverted light microscope. Duplicate plates were averaged.
Cells were harvested, pelleted, washed once in HBSS, and
counted before preparation of cytospins. Differential cell counts
(total of 200 cells each) were performed on stained cytospins to
assess percentages and calculate absolute numbers of neutrophilic
cells. To assess the effects of growth factor deprivation, cells were
placed into methylcellulose medium with or without GM-CSF
and incubated for 24 h before plating matched cultures in the
presence of GM-CSF. Results were expressed as a percentage
(CFU of growth factor–deprived culture/CFU of matched cul-
ture without growth factor deprivation 
 
3 
 
100).
 
Transplantation of Bone Marrow.
 
Essentially as described previ-
ously (4), total bone marrow isolated from tibias and femurs of
4–6-wk-old mice was divided for intravenous injection into 6–10
recipient mice (
 
z
 
1–3 
 
3
 
 10
 
6
 
 nucleated marrow cells/recipient).
6–12-wk-old FVB/N mice were prepared for transplantation by
cesium irradiation totaling 10 Gy, divided into two doses 3–6 h
apart. The results shown in Fig. 3 include five recipients of 
 
PML-
RAR
 
a
 
/BCL-2
 
 doubly transgenic marrow that was 0.75 FVB/N
strain, 0.25 BA strain; six recipients of matched 
 
PMLRAR
 
a
 
 sin-
gly transgenic marrow (0.75 FVB/N, 0.25 BA); eight recipients
of 
 
PMLRAR
 
a
 
/BCL-2
 
 doubly transgenic marrow (0.98 FVB/N,
0.02 BA); and 21 recipients of 
 
PMLRAR
 
a
 
 singly transgenic mar-
row (1.0 FVB/N). The difference in survival of recipients of
doubly transgenic and singly transgenic marrow was statistically
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significant whether the data were analyzed as a whole or as sub-
groups.
 
Comparative Genomic Hybridization.
 
Comparative genomic
hybridization was performed as described previously (30, 31) at
the Molecular Cytogenetics Core Facility, Comprehensive Can-
cer Center, University of California at San Francisco.
 
Retinoic Acid/Arsenic Treatment.
 
As described previously, mice
were treated by subcutaneous implantation of a 21-d release pellet
containing 5 mg tRA or placebo (Innovative Research of Amer-
ica; reference 4), and/or by daily intraperitoneal injection of
As
 
2
 
O
 
3
 
 (arsenic) at a dose of 5 
 
m
 
g/g body wt (32).
 
Statistical Analysis.
 
The software program Statistica (v.4.1 for
Macintosh) was used to prepare Kaplan-Meier curves and to
compare survival using the Wilcoxon test. Other statistical analy-
ses were performed with Excel (v.5.0/95) using the Student’s 
 
t
 
test, two-tailed distribution, and unequal variance. Comparisons
are with control animals unless otherwise noted.
 
Results
 
BCL-2 Cooperates with PMLRAR
 
a
 
 to Impair Neutrophil
Maturation and Expand Myeloid Progenitors.
 
Previously, we
developed a mouse model of APL by expressing PML-
RAR
 
a
 
 in the neutrophilic cells of transgenic mice (4).
PMLRAR
 
a
 
 had a modest effect on neutrophil differentia-
tion but did not initially arrest maturation. Some of the
 
PMLRAR
 
a
 
 transgenic mice went on to develop acute leu-
kemia with promyelocytic features. The latency and lim-
ited penetrance of the leukemic phenotype indicated that
in this mouse model, additional events were required to
cooperate with PMLRAR
 
a
 
 in the genesis of acute leuke-
mia. In our effort to identify genetic changes that can co-
operate with PMLRAR
 
a
 
 to induce leukemia, we consid-
ered previous studies indicating that PMLRAR
 
a
 
 induces
apoptosis of many cell lines (15) and evidence that apopto-
sis can be a critical regulator of malignant transformation in
vivo (33).
To assess the hypothesis that suppression of apoptosis co-
operates with PMLRAR
 
a
 
 in leukemogenesis, we crossed
 
MRP8-PMLRAR
 
a
 
 transgenic mice with 
 
MRP8-BCL-2
 
transgenic mice (27). Previous studies of 
 
MRP8-BCL-2
 
transgenic mice indicated that (a) the 
 
BCL-2 transgene in-
hibited apoptosis of neutrophils but not their engulfment
by macrophages (27), (b) the transgene inhibited apoptosis
of monocytes as well as rescued macrophages and partially
reversed osteopetrosis in op/op mice (34), (c) the transgene
Figure 1. BCL-2 cooperates with PMLRARa to impair neutrophil
production in vivo. (A) Peripheral blood. White blood cell count (WBC,
1,000/mL), hemoglobin (HGB, g/dL), and platelet count (PLT, 100,000/
mL) are shown. Littermate controls, n 5 6; PMLRARa, n 5 5; BCL-2,
n 5 4; and PMLRARa/BCL-2, n 5 6. Platelet count was increased in
PMLRARa/BCL-2 mice (P 5 0.002). (B) Peripheral blood. Absolute
cell counts (1,000/mL). Littermate controls, n 5 6; PMLRARa, n 5 4;
BCL-2, n 5 4; and PMLRARa/BCL-2, n 5 6. Neutrophils were de-
creased in BCL-2 and PMLRARa/BCL-2 mice (P 5 0.01). Monocytes
were increased in PMLRARa/BCL-2 mice (P 5 0.02). (C) Bone mar-
row. Percentages of nucleated cells were derived from 400 cell differential
counts of Wright’s Giemsa-stained bone marrow smears. Blast1Pro, blasts
and promyelocytes; Imm Neut, neutrophilic myelocytes and metamyelo-
cytes; Mat Neut, neutrophilic band, mature ring, and polymorphonuclear
forms; Lymph, lymphocytes; Eosin, eosinophils. Littermate controls, n 5
6; PMLRARa, n 5 4; BCL-2, n 5 4; PMLRARa/BCL-2, n 5 6. In
PMLRARa mice, blasts plus promyelocytes were increased (P 5 0.01).
In BCL-2 mice, blasts plus promyelocytes were increased (P 5 0.02), im-
mature neutrophils were increased (P 5 0.04), and mature neutrophils
were decreased (P 5 0.02). In PMLRARa/BCL-2 mice, blasts plus promyelocytes were increased (P 5 0.001), immature neutrophils were decreased
(P 5 0.003), mature neutrophils were decreased (P 5 0.0004), and lymphocytes were decreased (P 5 0.002). Graphs depict arithmetic means 6 SD.
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inhibited Fas-induced apoptosis of myeloid progenitors
(35), and (d) in the context of FASlpr/lpr mice, the BCL-2
transgene contributed to the development of a lethal prolif-
eration of myeloid cells (35). These results showed that the
BCL-2 transgene was able to suppress apoptosis of myeloid
cells and contribute to myeloid neoplasms.
MRP8-BCL-2 transgenic mice were mated with MRP8-
PMLRARa mice to examine the effects of the combina-
tion of transgenes on hematopoiesis. In the peripheral
blood, total leukocyte counts and hemoglobin levels of
3–5-wk-old transgenic mice were normal (Fig. 1 A). Singly
transgenic mice had normal platelet counts, whereas those
of doubly transgenic mice were elevated. PMLRARa
transgenic mice had normal peripheral blood neutrophil
counts, but mice expressing BCL-2 alone or in combina-
tion with PMLRARa were neutropenic (Fig. 1 B). De-
creased neutrophil counts were previously observed in
MRP8-BCL-2 transgenic mice (34). In the bone marrow,
both PMLRARa and BCL-2 singly transgenic mice exhib-
ited a shift from mature neutrophilic cells to immature
neutrophilic cells with a small increase in promyelocytes.
Doubly transgenic mice had very few neutrophilic cells be-
yond the promyelocyte stage (Fig. 1 C). Whereas the bone
marrow of singly transgenic mice looked modestly different
from control mice (Fig. 2, A–C), doubly transgenic bone
marrow was filled with immature cells and morphologically
resembled acute leukemia (Fig. 2 D). However, unlike leu-
kemic animals, the organs of these doubly transgenic mice
had a near normal appearance (Fig. 2, E–J).
We also assessed proliferation and apoptosis in the trans-
genic mice (Table I). PMLRARa did not discernibly alter
the number of proliferating or apoptotic cells detected in
bone marrow. BCL-2 increased the number of proliferating
cells, and the combination of transgenes increased both pro-
liferation and apoptotic cell numbers. Bone marrow histol-
ogy provided additional evidence of increased cell turnover
in doubly transgenic bone marrow; compared with control,
increased numbers of tingible body macrophages were
present (Fig. 2, K and L). The increased proliferation in
doubly transgenic mice is consonant with the presence of
Figure 2. PMLRARa and BCL-2
transgenes cooperate to arrest neu-
trophil differentiation. (A–D) Bone
marrow morphology: (A) Control
(Cntl); (B) preleukemic PMLRARa
(PR); (C) BCL-2; (D) preleukemic
PMLRARa/BCL2 (Pre PR/B).
Wright’s Giemsa stain; original mag-
nifications: 3330. Immature cells
are not disseminated in preleukemic
doubly transgenic mice. (E–F)
Spleen. Red pulp (r); white pulp
(w). (G–H) Liver. (I–J) Kidney. (E,
G, and I) Control. (F, H, and J)
Preleukemic PMLRARa/BCL-2.
Hematoxylin and eosin; original
magnifications: 366. Tingible body
macrophages are increased in pre-
leukemic PMLRARa/BCL-2 mice.
(K and L) Bone marrow histology.
(K) Control. (L) Preleukemic PML-
RARa/BCL-2. Arrows indicate se-
lected macrophages. Hematoxylin
and eosin; original magnifications:
3165.
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increased promyelocytes because promyelocytes, unlike
mature neutrophils, are mitotically active. The increase in
apoptotic cells likely reflects the fact that in some settings,
such as growth factor deprivation, BCL-2 delays but does
not prevent cell death (36). The combination of BCL-2 and
PMLRARa caused an accumulation of numerous imma-
ture myeloid cells in the bone marrow. These cells could
proliferate, but very few differentiated into mature neutro-
phils. BCL-2 appeared unable to block indefinitely the
death of the resulting expanded promyelocyte population.
Methylcellulose cultures were performed to examine the
effects of the transgenes on myeloid colony formation in
vitro (Table II). PMLRARa did not alter the number of
colonies formed in GM-CSF or G-CSF. In contrast, BCL-2
resulted in increased colonies, an effect that was statisti-
cally significant for doubly transgenic bone marrow. The
effect of growth factor deprivation on CFU was also as-
sessed for singly transgenic mice. Matched GM-CSF cul-
tures of control, PMLRARa, and BCL-2 bone marrow
cells were plated with or without 24 h of growth factor
deprivation. Both PMLRARa and BCL-2 resulted in a
trend towards enhanced survival (control 61 6 7%, n 5 6;
PMLRARa 77 6 17%, n 5 6, P 5 0.07; BCL-2 95 6
14%, n 5 4, P 5 0.01). With regard to differentiation, PML-
RARa, BCL-2, and PMLRARa/BCL-2 transgenic bone
marrows gave rise to a decreased percentage of neutrophils,
accompanied by increased immature and monocytic cells.
Of note, although the combination of BCL-2 and PML-
RARa caused profound neutropenia in vivo, neutrophil
maturation was not completely blocked in bone marrow
Table I. Bone Marrow Proliferation and Apoptosis in Nonleukemic Animals
Transgenic mice Proliferation* Apoptosis‡
Control 24.6 6 3.4 3.02 6 1.08
PMLRARa 23.7 6 2.1 NS 3.07 6 1.31 NS
BCL-2 31.0 6 3.1 P 5 0.03 5.98 6 2.87 NS
PMLRARa/BCL-2 36.9 6 1.3 P 5 0.003 10.11 6 1.27 P 5 0.0002
Bone marrows of mice were harvested and analyzed without prior culture to assess the effects of the transgenes on proliferation and apoptosis in vivo.
Data are shown as arithmetic means 6 SD. For each group, n = 4. P values for comparisons with control are shown. NS, not significant.
*Percent S phase.
‡Percent live CD18+ (nonerythroid) cells stained by 7-AAD.
Table II. Methylcellulose Cultures of Bone Marrow of Nonleukemic Animals
Colonies
Immature
cells
Monocytes/
macrophages Neutrophilic cells Total cells Neutrophilic cells
n/ml % % % 1,000/ml 1,000/ml
GM-CSF
Control 96 6 25 9.7 6 4.6 53.6 6 2.9 33.8 6 3.4 149 6 39 51.1 6 16.8
PMLRARa 106 6 16 9.3 6 2.3 76.4 6 7.1,
P 5 0.001
10.8 6 6.5,
P , 0.001
192 6 72 17.4 6 6.3,
P 5 0.008
BCL-2 179 6 78 13.0 6 1.4 61.7 6 10.6 19.3 6 7.8,
P 5 0.03
323 6 182 74.7 6 61.1
PMLRARa/BCL-2 354 6 147,
P 5 0.007
12.4 6 4.8 77.6 6 6.4,
P , 0.001
7.7 6 5.6,
P , 0.001
732 6 428,
P 5 0.02
45.7 6 41.2
G-CSF
Control 40.0 6 18 22.1 6 9.4 37.3 6 10.9 40.4 6 17.5 16.5 6 8.4 5.7 6 2.2
PMLRARa 36.0 6 10 30.7 6 12 50.5 6 11.8 17 6 5.5,
P 5 0.04
7.7 6 7.5 1.1 6 0.8,
P 5 0.007
BCL-2 70.0 6 20 32.6 6 13.1 57.5 6 21.3 9.3 6 9.1,
P 5 0.01
21.8 6 8.3 1.8 6 1.3,
P 5 0.01
PMLRARa/BCL-2 114.0 6 45,
P = 0.009
40.0 6 26 55.8 6 25.4 3.5 6 2.7,
P 5 0.009
51.7 6 39.7 2.1 6 3,
P 5 0.05
Bone marrows of mice were harvested and cultured in duplicate at 50,000 cells/ml culture in the presence of either GM-CSF or G-CSF. On day 7,
colonies/plate were counted, cells were harvested, pooled from duplicate plates, and counted. Immature cells, monocytes/macrophages, and
neutrophilic cells were identified among 200 cells counted on Wright’s Giemsa-stained cytospins of pooled cells. Data are shown as arithmetic
means 6 SD. For each group, n = 4–6. P values (excluding values .0.05) for comparisons with control are shown.
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cultures. In GM-CSF, absolute numbers of neutrophils in
BCL-2 and PMLRARa/BCL-2 cultures were normal be-
cause increased colony numbers offset the relative decrease
in neutrophil maturation. However, in G-CSF absolute
numbers of neutrophils were decreased. These results sug-
gest that PMLRARa and BCL-2 impeded neutrophil dif-
ferentiation of myeloid precursors. Altogether, our obser-
vations of doubly transgenic animals showed that BCL-2
expanded myeloid progenitors, allowed increased numbers
of cells to proliferate, and enhanced the ability of PML-
RARa to inhibit neutrophil differentiation.
BCL-2 Cooperates with PMLRARa to Initiate Leukemia.
The experiments described above were performed on
matched 3–5-wk-old littermates. We noted that mice that
inherited both transgenes were smaller than littermates at 3
wk of age, had the skin abnormalities we have seen in our
PMLRARa transgenics (4), and died between 4 and 6 wk
of age. To assess the degree to which these deaths were due
solely to a hematopoietic disorder or in part to nonhemato-
poietic effects of the transgenes, we harvested bone marrow
from doubly transgenic mice and used this marrow to re-
constitute lethally irradiated nontransgenic animals. Mar-
row harvested from PMLRARa singly transgenic mice was
similarly transplanted. Transplantation of either PML-
RARa transgenic or PMLRARa/BCL-2 doubly trans-
genic bone marrow rescued recipient mice from lethal irra-
diation. Recipients remained healthy for 3 mo or more
after transplantation, suggesting that the early deaths of un-
Figure 3. BCL-2 cooperates with PML-
RARa to initiate leukemia. Lethally irradi-
ated nontransgenic FVB/N mice were
reconstituted with bone marrow from
PMLRARa or PMLRARa/BCL-2 trans-
genic mice. Kaplan-Meier curves are
shown. All PMLRARa/BCL-2 mice died
of leukemia. Mortality among PMLRARa
mice from causes other than leukemia was
censored at the date of death. PMLRARa/
BCL-2, n 5 13; PMLRARa, n 5 27; P ,
0.00001.
Figure 4. PMLRARa and PMLRARa/BCL-2 leukemic mice are anemic, thrombocytopenic, and have bone marrow that is filled with promyelo-
cytes. (A) Peripheral blood. Results are displayed as in the legend to Fig. 1 A. Adult controls, n 5 7; PMLRARa leukemia, n 5 10; PMLRARa/BCL-2
leukemia, n 5 10. White blood cell count (WBC) was not significantly different among the groups. Hemoglobin (HGB) and platelet count (PLT) were
reduced in leukemic mice (P , 0.00001). (B) Bone marrow. Results are displayed as in the legend to Fig. 1 C. Adult controls, n 5 7; PMLRARa leu-
kemia, n 5 6; PMLRARa/BCL-2 leukemia, n 5 6. All values were significantly different in leukemic mice compared with controls (P , 0.00001 to
P 5 0.002), but were not significantly different between PMLRARa and PMLRARa/BCL-2 leukemias.
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transplanted doubly transgenic mice were, at least in part,
caused by nonhematopoietic effects of the transgenes.
Mice reconstituted with PMLRARa or PMLRARa/
BCL-2 bone marrow were observed for the development
of leukemia. Leukemias developed more rapidly in mice
coexpressing PMLRARa and BCL-2 than in mice ex-
pressing PMLRARa alone (median time to leukemia 127
vs. 257 d; Fig. 3). All mice reconstituted with doubly trans-
genic bone marrow succumbed to leukemia by 196 d of
age. Similar to the leukemias that arose from singly trans-
genic PMLRARa mice, leukemias arising from PML-
RARa/BCL-2 doubly transgenic mice were characterized
by anemia and thrombocytopenia, and by bone marrow
that was effaced by cells at the blast-promyelocyte stage of
differentiation (Figs. 4 and 5 A). Although there was a
trend towards increased peripheral white blood cell counts
in PMLRARa/BCL-2 leukemias, this trend was not statis-
tically significant (P . 0.05).
Dissemination Appears to Be a Central Characteristic of
AML. PMLRARa/BCL-2 transgenic mice had bone
marrow that morphologically resembled acute leukemia
(Figs. 2 D and 5 A), yet mice whose bone marrow ex-
pressed both transgenes did not become ill for a period of
3–7 mo. Therefore, we sought to identify differences be-
tween preleukemic and overtly leukemic, doubly trans-
genic animals. Bone marrow differential counts showed
very low numbers of maturing neutrophils in preleukemic
and leukemic animals (Fig. 1 C, PMLRARa/BCL-2; Fig.
4 B). However, in the leukemias suppression of normal he-
matopoiesis was evident: there was a marked decrease of
nucleated erythroid cells in the bone marrow, and in con-
trast to preleukemic animals, the leukemic mice were ane-
mic and thrombocytopenic (Figs. 1 A and 4 A). Further-
more, in the leukemic mice, immature neutrophilic cells
were disseminated. Small numbers of promyelocytes were
present in the peripheral blood, and the spleens, livers, and
kidneys in leukemic mice were enlarged and contained in-
filtrates of leukemic cells (Fig. 5, B–D). The existence of a
prolonged preleukemic state in PMLRARa/BCL-2 mice
suggests that the suppression of normal hematopoiesis and
dissemination of leukemic cells observed in AML are not a
direct consequence of arrested differentiation.
Acquired Chromosomal Abnormalities Are Common in Mu-
rine APL. Preleukemic, doubly transgenic mice initially
produced adequate red blood cells and platelets and did not
become ill for 3–7 mo. These findings indicated that the
combination of BCL-2 and PMLRARa was sufficient to
initiate but not complete leukemic transformation. There-
fore, we sought to identify additional genetic changes in
our leukemias. Comparative genomic hybridization was
performed on 30 murine APLs, including 20 PMLRARa
leukemias and 10 PMLRARa/BCL-2 leukemias. Chro-
mosomal copy number abnormalities were observed in 17/20
PMLRARa leukemias and 9/10 PMLRARa/BCL-2
leukemias. Gain of chromosomes 7, 8, 10, and 15 and loss
of chromosome 2 occurred in three or more samples in-
cluding both PMLRARa and PMLRARa/BCL2 leuke-
mias (Fig. 6). Losses of the X chromosome from female
samples and the Y chromosome from male samples were
also observed. These results identify chromosomal regions
whose loss or gain may complete the process of leukemic
transformation initiated by PMLRARa.
Murine APL Expressing BCL-2 Responds to Retinoic Acid
and Arsenic Trioxide. We assessed whether the expression
of BCL-2 influenced the ability of tRA therapy to cause
differentiation and prolong survival of mice with APL.
Nontransgenic mice received intravenous injections of 5 3
106 spleen cells from leukemia 2995A4, which expresses
both PMLRARa and BCL-2 transgenes. In one experi-
ment, 32 d after the injection of leukemic cells, three mice
were treated with placebo and three with tRA. The pla-
cebo-treated mice died on days 3 and 5, and five died after
initiation of therapy, whereas tRA-treated mice died on
days 17, 25, and 33. The difference in survival was signifi-
cant (P 5 0.04). In a second experiment, groups of six mice
were treated 14 d after the injection of leukemic cells;
again, tRA prolonged survival (Fig. 7 A). The prolongation
in survival we observed (median 42 d, range 11–73) was
comparable to the increase in survival seen in recipients of a
PMLRARa leukemia that was similarly treated (median 41 d,
range 33–175; reference 32). tRA induced neutrophilic
differentiation of leukemic blasts coexpressing PMLRARa
and BCL-2 (Fig. 7 B), but did not abrogate expression of
the transgenes as assessed by Western blot analysis (data not
shown).
Figure 5. Leukemic transformation is characterized by dissemination of
immature cells. Leukemic PMLRARa/BCL-2. (A) Bone marrow mor-
phology. Wright’s Giemsa stain; original magnification: 3330. (B)
Spleen. l, leukemic infiltrate. (C) Liver. (D) Kidney. (B–D) Hematoxylin
and eosin; original magnifications: 366.
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We also examined whether arsenic and tRA were an ef-
fective combination therapy for APL expressing BCL-2. In
three experiments, nontransgenic mice received intrave-
nous injections of 107 leukemic 2995A4 cells. After 15 d,
mice were treated with tRA and/or arsenic for 4 d, two
mice per group, and then killed. Similar to what was previ-
ously observed for murine APL that does not express BCL-2
(32), arsenic-induced apoptosis and some differentiation,
and the combination of arsenic and tRA, caused rapid re-
gression of the leukemia. 4 d of therapy decreased spleen
size (control, 0.57, 0.46 g; tRA, 0.21, 0.20 g; arsenic, 0.40,
0.30 g; tRA/arsenic: 0.10, 0.09 g; representative data from
one of three experiments). In the liver, tRA caused regres-
sion but not the disappearance of disease, and the addition
of arsenic eliminated the visible leukemic cell population
(Fig. 7 C). These results suggest that APL cells expressing
BCL-2 remain sensitive to arsenic plus tRA combination
therapy.
Discussion
Expression of BCL-2 in mice that also express the APL-
associated PMLRARa fusion protein caused a marked ac-
cumulation of immature myeloid cells and accelerated the
development of leukemia. Progression from preleukemia to
acute leukemia was characterized by suppression of normal
hematopoiesis and dissemination of leukemic cells. Addi-
tional genetic changes accompanied this transition from ab-
normal neutrophil maturation to lethal disease.
A Role for Suppression of Apoptosis in APL Pathogenesis.
The possible role of apoptosis in APL pathogenesis has
been unclear. Whereas PMLRARa induces cell death in
many cell lines, it also inhibits apoptosis of some myeloid
cell lines and primary myeloid cells. We anticipated that
BCL-2 might cooperate with PMLRARa to initiate leu-
kemia. On the other hand, given the ability of PMLRARa
itself to block apoptosis, it was possible that BCL-2 would
have little impact on leukemogenesis. We observed that the
antiapoptotic protein BCL-2 did cooperate with PML-
RARa to initiate leukemia, indicating that genetic changes
that suppress apoptosis can cooperate with the PMLRARa
fusion in APL.
The MRP8-BCL-2 transgene has been demonstrated to
increase survival of myeloid cells (27, 34, 35, and our re-
sults). We observed increased CFU and young myeloid
forms in bone marrows of BCL-2 and doubly transgenic
mice. It is likely that this increase is in part attributable to
the ability of BCL-2 to enhance survival of immature my-
eloid cells. BCL-2 makes cells less dependent on external
survival signals. BCL-2 did not, however, permit unlimited
survival of immature cells. We speculate that the preleuke-
mic, doubly transgenic cells remained responsive to extra-
cellular signals that limited their expansion to hematopoi-
etic microenvironments. Nevertheless, it appears that by
Figure 6. Murine APL is characterized
by karyotypic abnormalities. Results of
comparative genomic hybridization of 30
APLs (11 female, 19 male) are shown, in-
cluding 20 PMLRARa and 10 PML-
RARa/BCL-2 leukemias. Ideograms of
mouse chromosomes are numbered. Each
bar to the left of chromosomes indicates a
region lost in one leukemic sample. Each
bar to the right of chromosomes indicates a
region gained in one sample. Each wide bar
represents chromosomal gain in 10 samples.
Losses of the X chromosome were seen in
female samples.
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Figure 7. APL expressing PMLRARa and BCL-2 is responsive to therapy. (A and B) Unirradiated nontransgenic FVB/N mice received 5 3 106
PMLRARa/BCL-2 leukemic cells by intravenous injection. (A) 14 d after injection of leukemic cells, 5 mg placebo (n 5 6) or tRA (n 5 6) pellets (21-d
release) were implanted into mice. Kaplan-Meier curves are shown. P 5 0.02. (B) Bone marrow morphology. Recipients of PMLRARa/BCL-2 leuke-
mic cells were treated with placebo or tRA when ill. PL, placebo-treated; RA, tRA-treated, day 11. Wright’s Giemsa stain; original magnification:
3455. (C) FVB/N mice received 107 PMLRARa/BCL-2 leukemic cells. 15 d after injection, mice were treated with tRA and/or arsenic for 4 d. Rep-
resentative sections of livers are shown. PL, placebo: a leukemic infiltrate is present in the periportal and parenchymal regions of the liver; inset shows im-
mature myeloid cells; tRA, retinoic acid: leukemic cells are much reduced; inset shows hepatocytes accompanied by smaller residual leukemic cells, ar-
rowhead indicates a maturing neutrophil. As, arsenic; leukemic infiltrate present; arrows (inset) indicate condensed nuclei of apoptotic cells. tRA/As,
retinoic acid/arsenic: leukemic cells are not seen. Hematoxylin and eosin: original magnifications: 3125; inset 3625.
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expanding the population of immature myeloid cells in
PMLRARa transgenic mice, BCL-2 made it inevitable
that additional leukemogenic mutations would accumulate.
Expression of BCL-2 therefore promotes promyelocyte
transformation but is not sufficient to complete this process.
Interestingly, whereas BCL-2 may facilitate the acquisition
of genetic changes that induce acute leukemia in PML-
RARa transgenic mice, it does not appear to alter the type
of chromosomal changes that occur.
Cytogenetic Changes in Murine APL. The t(15;17) trans-
location is present as an isolated karyotypic abnormality in
the majority of APL patients at presentation. However, ad-
ditional karyotypic abnormalities are observed in 24–39%
of untreated APL patients (37–40). The fact that a substan-
tial minority of new APL cases have additional cytogenetic
changes provides evidence that human APL results from a
combination of acquired mutations. The most common
additional abnormality is trisomy 8, which is seen in z17%
of patients at presentation. Other recurrent aberrations in-
clude loss of chromosome 9q and isochromosome of the
long arm of the derivative chromosome 17. The particular
genes through which these additional cytogenetic changes
may contribute to leukemia have not been identified.
Some of the changes seen in murine APL correspond to
karyotypic abnormalities in human APL. Murine chromo-
somes 8 and 15 contain regions homologous to human
chromosome 8. The area of loss we noted on mouse chro-
mosome 2 contains genes that in humans are located on
human chromosome 9q. In the broader context of attempts
to understand leukemia pathogenesis in mice, the gain of
chromosome 15 and the loss of chromosome 2 have been
observed previously. Gibbons et al. (41) observed a com-
mon gain of chromosome 15 in B/myeloid leukemias that
arose in irradiated Em-BCL-2 mice. The authors suggested
that the presence of BCL-2 permitted cells damaged by ra-
diation to tolerate chromosomal damage, and the subse-
quently damaged cells gave rise to the observed leukemias.
In our experiments, BCL-2 could have similarly tolerized
early myeloid cells to spontaneous genetic changes includ-
ing a pathogenic gain of chromosome 15. Loss of murine
chromosome 2 has been observed in radiation-induced
myeloid leukemias in mice (for a review, see reference 42).
The region of murine chromosome 2 identified in these
leukemias was lost in all four APLs in which we observed
copy number changes on chromosome 2. Of interest, an-
other group studying the effects of PMLRARa, under the
control of a different promoter in a different strain of mice,
has also identified recurrent gain of chromosome 15 and
recurrent loss of chromosomes 2, X, and Y in their leuke-
mias (43). The chromosome copy number abnormalities
observed in murine APLs may facilitate identification of
genetic changes that cooperate with PMLRARa to cause
acute leukemia.
BCL-2 Effects on Neutrophil Differentiation. Although
PMLRARa can inhibit differentiation, its effects on neu-
trophilic differentiation of primary bone marrow cells were
modest and most apparent in vitro (Table II). In vivo,
BCL-2 cooperated with PMLRARa to block maturation
at the promyelocyte stage. Given the central role of BCL-2
family members in regulating cell death, the inhibition of
neutrophil differentiation in PMLRARa transgenic mice
brought by coexpression of BCL-2 is likely an indirect ef-
fect of BCL-2. Enhanced survival of neutrophil precursors
may abrogate signals within the bone marrow that normally
stimulate promyelocytes to differentiate into mature neu-
trophils. The finding that mature erythroid cells stimulate
the death of erythroid progenitors (44) raises the possibility
that interactions between mature and immature myeloid
cells play a role in neutrophil maturation. Such interactions
could be disrupted by enhanced survival of immature ele-
ments. On the other hand, our data are consistent with the
speculative idea that BCL-2 may directly influence neutro-
phil maturation. Our finding that BCL-2 transgenic mar-
row gave rise to relatively decreased neutrophils in vitro
might reflect enhanced production of monocytic cells, but,
alternatively, this decrease could reflect a cell autonomous
effect of BCL-2 on neutrophil differentiation. In previous
studies, BCL-2 did not block tRA-induced differentiation
of HL-60 cells (45), but BCL-2 did delay neutrophilic mat-
uration of 32DCl3 cells in response to G-CSF (46). An-
other finding suggesting that, in some settings, BCL-2
family members might directly influence neutrophil differ-
entiation is the observation that tRA-mediated differentia-
tion of APL cells is accompanied by caspase activation (13).
BCL-2 family members might influence differentiation
through an activity that is distinct from their effects on cell
survival. Such a possibility has precedent: BCL-2 has an ef-
fect on proliferation separable from its effect on survival
(47).
Multistep Pathogenesis for APL. The pathogenesis of hu-
man APL may parallel that of murine APL. The acquisition
of the t(15;17)(q22,q11.2) with resulting expression of PML-
RARa could initiate leukemia. Increased expression of
BCL-2, or other genetic changes that enhance survival and
impair differentiation of the initiated cells, may occur in
some patients and facilitate the acquisition of genetic
changes that result in acute leukemia. Further study of hu-
man APLs could inform our understanding of the role of
BCL-2–like proteins in the human disease. Although BCL-2
expression was not seen in one study of APL cases (21),
subsequent reports indicated that BCL-2 is expressed in
most APLs (22–25, 48). Elucidating whether this BCL-2
expression is because of a genetic lesion in the BCL-2 gene
or a downstream result of other lesions should be of value,
as should assessing the expression of other BCL-2 family
members in APL.
It is notable that the t(15;17) translocation is likely to
have effects that are more pronounced than those caused by
PMLRARa alone. Similar to BCL-2 expression, loss of
Pml, a genetic event that suppresses apoptosis, facilitated the
development of acute leukemia in CathepsinG-PMLRARa
transgenic mice (49). The reciprocal fusion protein,
RARaPML, also increased the penetrance of leukemia in
mice expressing PMLRARa (50). Given the fact that the
incidence of t(15;17)-associated myeloid leukemia does not
increase with age (51), we favor a model in which the
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translocation initiates the disease and additional required
genetic changes may accumulate in a relatively brief period
of time.
BCL-2 Does Not Block the Response to APL Therapy.
Downregulation of BCL-2 accompanies the differentiation
of APL cells that is induced by tRA (52), and this down-
regulation may be important for some effects of tRA (13).
We found that overexpression of BCL-2 did not block the
differentiative effect of tRA. Similarly, BCL-2 might have
blocked the therapeutic effect of arsenic because arsenic is
thought to induce remissions primarily by stimulating
apoptosis of the APL blasts (53–55). The fact that murine
APL overexpressing BCL-2 still responded to arsenic
suggests that arsenic can overcome a BCL-2–mediated
delay in apoptosis. This result is also consistent with the
hypothesis that differentiative effects of arsenic contribute
to its therapeutic value. Although we studied the response
of a single transplantable PMLRARa/BCL-2 leukemia to
tRA and arsenic and, therefore, have not addressed possi-
ble heterogeneity among such leukemias, our results nev-
ertheless indicate that BCL-2 expression can be associated
with an intact response. Thus, human APLs that overex-
press BCL-2 or have acquired analogous changes may re-
main responsive to the novel APL therapies, tRA and ar-
senic.
Is Dissemination of Myeloid Leukemia Cells the Equivalent of
Metastasis of Solid Tumors? Discussions of AML pathogen-
esis often focus on the inhibition of differentiation charac-
teristic of the disease. The existence of a preleukemic state
in PMLRARa/BCL-2 transgenic mice characterized by
maturation that is nearly arrested suggests that additional
features of AML, including suppression of normal hemato-
poiesis and dissemination of leukemic cells, are not the di-
rect result of inhibited differentiation. AML may result
from two fundamental abnormalities: (a) a relative inhibi-
tion of differentiation that is accompanied by (b) a relative
autonomy that allows the leukemic cells to survive and
proliferate outside of their normal microenvironment. The
idea that survival and proliferation outside of the normal
microenvironment are central to AML parallels the concept
that for solid tumors, invasion and metastasis define malig-
nancy. In our APL model, although BCL-2 enhances cell
survival, other genetic lesions are still required to fully
overcome normal growth controls.
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